Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDC-1001 + pertuzumab
- Development stage
- Unknown
- Lead developer
- Bolt Biotherapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BDC-1001 + pertuzumab is a combination therapy being investigated for HER2-positive breast cancer. BDC-1001 is a HER2-targeted Immune-Stimulating Antibody Conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist. Pertuzumab (Perjeta) binds to a distinct HER2 epitope from the trastuzumab component of BDC-1001, which may increase the amount of clustered Fc or "eat me signals" on the tumor surface. This combination is hypothesized to trigger enhanced antibody-dependent cellular phagocytosis, a key element of the BDC-1001 mechanism of action, resulting in further propagation of BDC-1001-driven immune activation and anti-tumor efficacy.
- Brand names
- Perjeta
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)
Beyond the preview
Go deeper on BDC-1001 + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BDC-1001 + pertuzumab.